Incapacitating solar urticaria: successful treatment with omalizumab
An. bras. dermatol; 94 (3), 2019
Publication year: 2019
Abstract:
Solar urticaria is a rare form of physical urticaria mediated by immunoglobulin E. The lesions appear immediately after the sun exposure, interfering with the patient's normal daily life. Omalizumab, a monoclonal anti-IgE antibody, has been recently approved for the treatment of chronic spontaneous urticaria, and the latest reports support its role also in the treatment of solar urticaria. Hereby, we report a case of solar urticaria refractory to conventional treatment strategies, with an excellent response to treatment with omalizumab and phototesting normalization.
Antialérgicos/uso terapéutico, Omalizumab/uso terapéutico, Trastornos por Fotosensibilidad/diagnóstico, Trastornos por Fotosensibilidad/tratamiento farmacológico, Trastornos por Fotosensibilidad/etiología, Luz Solar/efectos adversos, Urticaria/diagnóstico, Urticaria/tratamiento farmacológico, Urticaria/etiología